Effect of 3,4-diaminopyridine phosphate in symptomatic SOD1-G93A mice

Swathi Beladakere Ramaswamy, J. Stanford, S. Iyadurai, R. Govindarajan, R. Barohn
{"title":"Effect of 3,4-diaminopyridine phosphate in symptomatic SOD1-G93A mice","authors":"Swathi Beladakere Ramaswamy, J. Stanford, S. Iyadurai, R. Govindarajan, R. Barohn","doi":"10.17161/rrnmf.v2i5.15641","DOIUrl":null,"url":null,"abstract":"Objective: To study the effect of 3,4-diaminopyridine phosphate (3,4-DAPP) on body weight, grip strength, neurological score and survival in symptomatic SOD1-G93A mice. \n  \nMethod: We administered 3,4-diaminopyridine phosphate (3,4-DAPP) at 0, 8, and 16 mg/kg to SOD1-G93A mice 5 days/week beginning at 90 days of age. We measured body weight, grip strength, neurological score and survival in this model of ALS. \n  \nResults: 3,4-DAPP had no influence on body weight, grip strength, neurological score or survival in this transgenic mouse model. \n  \nConclusion: Our study showed that 3,4-DAPP administration had no effects on survival, body weight, grip strength and neurological score of mice with SOD1 mutation. Since the results of this study are of limited significance, larger animal studies are required to investigate the utility of 3,4-DAPP.","PeriodicalId":309700,"journal":{"name":"RRNMF Neuromuscular Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RRNMF Neuromuscular Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17161/rrnmf.v2i5.15641","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To study the effect of 3,4-diaminopyridine phosphate (3,4-DAPP) on body weight, grip strength, neurological score and survival in symptomatic SOD1-G93A mice.   Method: We administered 3,4-diaminopyridine phosphate (3,4-DAPP) at 0, 8, and 16 mg/kg to SOD1-G93A mice 5 days/week beginning at 90 days of age. We measured body weight, grip strength, neurological score and survival in this model of ALS.   Results: 3,4-DAPP had no influence on body weight, grip strength, neurological score or survival in this transgenic mouse model.   Conclusion: Our study showed that 3,4-DAPP administration had no effects on survival, body weight, grip strength and neurological score of mice with SOD1 mutation. Since the results of this study are of limited significance, larger animal studies are required to investigate the utility of 3,4-DAPP.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
3,4-二氨基吡啶磷酸对SOD1-G93A症状小鼠的影响
目的:研究3,4-磷酸二氨基吡啶(3,4- dapp)对SOD1-G93A症状小鼠体重、握力、神经系统评分及生存的影响。方法:从90日龄开始,以0、8、16 mg/kg的剂量给SOD1-G93A小鼠3,4-二氨基吡啶磷酸(3,4- dapp) 5天/周。我们测量了这个ALS模型的体重、握力、神经学评分和生存率。结果:3,4- dapp对小鼠体重、握力、神经学评分及存活均无影响。结论:我们的研究表明,3,4- dapp给药对SOD1突变小鼠的生存、体重、握力和神经学评分没有影响。由于本研究的结果意义有限,需要更大规模的动物研究来调查3,4- dapp的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Survival and multidisciplinary amyotrophic lateral sclerosis clinic care at a United States Veterans Affairs medical center Recurrent Guillian Barre’ Syndrome vs acute onset CIDP - study of 2 cases. Rhabdomyolysis and Exercise Intolerance in a 45-Year-Old Man A Worsening Problem in ALS: Insurance Barriers Between Drug Approvals and Patient Access Safety and tolerability of phenylbutyrate in inclusion body myositis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1